Business Description
Satellos Bioscience Inc. is a Canadian biotechnology company founded in 2018 and based in Toronto, focused on developing treatments for muscle-wasting diseases. Its lead drug candidate, SAT-3247, is a pill designed to treat Duchenne muscular dystrophy, a severe condition that progressively weakens the muscles. The company's research is supported by partnerships with the Ottawa Hospital Research Institute and the University of British Columbia, and it operates primarily in Canada and Australia.
